On October 5, 2015 FDA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
Full details...
http://hcvadvocate.blogspot.ca/2015/10/olysio-simeprevir-label-revised.html
On October 5, 2015 FDA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
Full details...
http://hcvadvocate.blogspot.ca/2015/10/olysio-simeprevir-label-revised.html